AbbVie Banks On “Pipeline In A Molecule” Strategy For Imbruvica
Executive Summary
AbbVie CEO Richard Gonzalez defended the roughly $21 billion purchase price it offered to pay for Pharmacyclics, citing bullish long-term sales projections for Imbruvica driven by indication expansion.
You may also be interested in...
Another Strong Quarter For AbbVie, But How Long Will Good Times Last?
With continued strong growth for Humira, AbbVie doubles down on confidence to protect the franchise with IP strategy. Imbruvica and Viekira Pak show growth, although the latter is flourishing only ex-US.
Merck Expands Immuno-Oncology Efforts, Calls MK-3475 A Pipeline In Itself
Rolling BLA for MK-3475 accepted for priority review with a PDUFA date of Oct. 28. Merck is undertaking or plans trials testing the anti-PD-1 candidate in 10 types of cancer and is seeking response signals in another 20 tumor types.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.